Veech Ketone Ester
(R)-3-hydroxybutyl (R)-3-hydroxybutyrateOne defined ester molecule linking D-BHB and R 1,3 butanediol. It is the intact ester that is manufactured, dosed and tested in human trials — not a mixture of the two hydrolysis products.
Molecule comparison · Metabolism
Ketone Ester vs R 1,3 Butanediol: How Their Metabolism Differs
Both end up as blood BHB. One arrives as a bonded molecule that already contains a ketone body; the other arrives as a precursor the liver has to convert first. What that difference does — and does not — mean, with the human kinetics laid out side by side.
Short answer
Short answer
The Veech Ketone Ester is one bonded molecule. Hydrolysis releases one D-BHB molecule directly and one R 1,3 butanediol molecule; the released R 1,3 butanediol is then converted in the liver into additional ketones. Free R 1,3 butanediol is a different starting molecule: an alcohol that has to be converted in the liver before any BHB appears.
Same downstream ketone body, different starting point — and that shows up in how much of each it takes to reach a given blood level, how the curve behaves, and which human outcome trials belong to which molecule. It does not make one route good and the other bad, and the shared downstream step for the released diol does not make the two starting molecules interchangeable. The defensible distinction is exact molecule, bond, pharmacokinetics, dose and outcome evidence.
Exact identity
Two molecules, one shared building block.
R 1,3 butanediol appears in both — free in one bottle, bonded to a ketone body in the other. That is what makes the comparison worth drawing carefully.
R 1,3 butanediol
(R)-butane-1,3-diolThe same diol on its own. It is a four-carbon alcohol; nothing in the bottle is a ketone body until the liver has done the conversion. Preclinical liver work indicates the R-form is converted more readily than the S-form, which racemic products also contain.
Chemical identity is the first link in any evidence chain: a study on one of these molecules is not a study on the other, however alike the blood reading looks afterwards. The product-match test starts here.
From bottle to blood
Two routes to the same ketone body.
Each step below is what the human and mechanistic literature actually describes. The chain stops where the papers stop — at ketones appearing in the blood.
Veech Ketone Ester
Hydrolysis first, then two products
- 1The ester is broken down after drinking.The intact ester is not detected in plasma; its hydrolysis products are. Blood D-BHB and acetoacetate both rise.Clarke et al. 2012 · Soto-Mota et al. 2020
- 2Hydrolysis releases D-BHB directly.D-BHB is already the circulating ketone body, so this portion does not require a hepatic conversion step to become D-BHB.One D-BHB molecule per ester molecule
- 3Hydrolysis also releases R 1,3 butanediol.The released diol is metabolized through the same hepatic conversion pathway described for free R 1,3 butanediol, generating additional ketones. The pathway itself is drawn on its own page.Clarke et al. 2012 · Panse & Gerk 2025
Free R 1,3 butanediol
Conversion first, then BHB
Free R 1,3 butanediol is absorbed as a precursor and converted in the liver before BHB appears in blood. The detailed pathway runs through an aldehyde intermediate and is covered separately.
Preclinical liver work indicates the R stereoisomer is converted to physiological ketone bodies more readily than the S stereoisomer found in racemic products.
See the R 1,3 butanediol → BHB pathwayThis page does not explain why free 1,3-butanediol has been reported to produce dizziness and euphoria in some human studies while the ester behaves differently; that mechanism is not established in the sources indexed here, and the tolerability findings are simply reported in the table below.
Side by side
Molecule, kinetics, dose and evidence.
Only source-verified numbers. Where two products were measured in the same people at the same dose, the row says so; everywhere else the figures come from different studies and are not directly comparable.
| Property | Veech Ketone Ester | R 1,3 butanediol (free) |
|---|---|---|
| What is in the bottle | One bonded molecule: D-BHB ester-linked to R 1,3 butanediol. | A free four-carbon alcohol. No ketone body present until conversion. |
| First step in the body | Hydrolysis. Intact ester not detected in plasma; D-BHB and acetoacetate rise.Clarke et al. · Regul Toxicol Pharmacol 2012 | Hepatic oxidation by alcohol and aldehyde dehydrogenases to BHB.Clarke 2012 · Panse & Gerk 2025 |
| Same 10 g, same peopleMatched-dose crossover, 12 fasted adults | About +1.7 mM rise above baseline.*Falkenhain et al. · J Diet Suppl 2024 | About +0.8 mM rise above baseline.* Peak about 1.2 mM at roughly 40 minutes.Falkenhain et al. 2024 · peak and timing as reported in Lowder et al. 2023 |
| Higher dosesDifferent studies — not comparable | 12–24 g of BHB-equivalent: peak about 2.8 mM. 714 mg/kg: peak 3.30 mM within 1–2 h. 50 g during a warm-up: about 3.5 mM through a 30-min time trial.Stubbs 2017 · Clarke 2012 · Poffé 2021 | 34.5 g of the R-form in three servings over an hour, fasted: mean peak 2.10 ± 0.97 mM about 2¼ hours after the first serving.Lowder et al. · Front Physiol 2023 · open-label, manufacturer-funded |
| Return toward baseline | Within 3–4 hours at 12–24 g. Elimination half-life 0.8–3.1 h for BHB.Stubbs 2017 · Clarke 2012 | Still about 1.1 mM five hours after the first of three servings.Lowder 2023 |
| Effect of a prior meal | A meal before the drink lowered peak D-BHB by about a third (2.2 vs 3.3 mM).Stubbs 2017 | Not measured in a controlled comparison in the sources indexed here. |
| Tolerability reported | Generally well tolerated in kinetics work; GI effects at the highest doses. At 50 g before a 30-min time trial, slightly higher GI distress — dizziness, bloating, nausea — than control, low overall.Clarke 2012 · Poffé 2021 | R-form, 34.5 g fasted: mostly no or mild symptoms; mild belching, nausea, dizziness and headache in some. Racemic form at 0.7 g/kg: nausea, euphoria and dizziness reported.Lowder 2023 · Shaw et al. · IJSNEM 2019 |
* Approximate rise above baseline calculated from the published baseline and peak values, not treatment-effect figures quoted verbatim from the paper. A twelve-person pharmacokinetic pilot in healthy, fasted adults; it measured BHB exposure, not performance or cognition. Rows marked “different studies” place numbers from separate protocols, populations and meters beside each other for orientation only.
What the metabolism comparison supports
Different molecules, different kinetics, different dosing
In the matched 10 g crossover, VKE produced roughly twice the rise in blood BHB as R 1,3 butanediol. Higher doses of free R 1,3 butanediol can raise BHB further, but dose comparisons across different studies and protocols are not head-to-head evidence.
What it does not support
Borrowing one molecule’s outcome trials for the other
The ester’s indexed human studies describe the ester. Outcome evidence for free R 1,3 butanediol has to come from trials of free R 1,3 butanediol — the transfer question has its own page.
Why it matters
Three places the metabolism difference changes how you read a study.
Same downstream BHB does not make the starting molecules, the kinetics, the dosing or the evidence interchangeable.
Becomes BHB ≠ is the same molecule
From evidence to the bottle
The chemistry is the product difference.
KetoneAid uses intact Veech Ketone Ester. It does not substitute free R 1,3 Butanediol, BHB salts, or an unbonded D-BHB + diol blend and treat the evidence as interchangeable.
If you want the VKE molecule discussed in VKE studies, choose a product that actually contains VKE.
Go deeper
From the molecule to the evidence.
The category
Exogenous ketones
Ketone ester, R 1,3 butanediol, BHB salts and D-BHB free acid — every type, what it is and what it has shown.
Compare the types The esterVeech Ketone Ester science
Where the molecule came from, how it was developed, and the human research behind it.
Explore VKE science The match testProduct-specific evidence
The five-link chain between a product and a claim — and why identity comes first.
Run the test The meterDoes raising BHB prove it works?
What a blood BHB reading is, what it is not, and how researchers get from a reading to a result.
Read the meter rightReferences cited on this page
- Clarke K, Tchabanenko K, Pawlosky R, et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul Toxicol Pharmacol. 2012;63(3):401–408. PubMed ↗Intact ester not detected in plasma; BHB peak 3.30 mM within 1–2 h at 714 mg/kg; BHB elimination half-life 0.8–3.1 h. Describes hepatic conversion of the released R 1,3 butanediol to D-BHB and acetoacetate by alcohol and aldehyde dehydrogenase.
- Soto-Mota A, Norwitz NG, Clarke K. Why a d-β-hydroxybutyrate monoester? Biochem Soc Trans. 2020;48(1):51–59. PubMed ↗Review: the monoester bond is cleaved, yielding BHB and butanediol; the latter is taken up by the liver and converted to BHB.
- Panse N, Gerk PM. Characterizing the Hepatic Metabolic Pathway of Ketone Ester and Subsequent Metabolites Using Human and Rat Liver Fractions. AAPS J. 2025;27(2):65. PubMed ↗Mechanism source only — pooled human and rat liver fractions, not a clinical trial. Rapid ester clearance; saturable R 1,3 butanediol metabolism in human liver fractions.
- Desrochers S, David F, Garneau M, Jetté M, Brunengraber H. Metabolism of R- and S-1,3-butanediol in perfused livers from meal-fed and starved rats. Biochem J. 1992;285:647–653. DOI ↗Preclinical (perfused rat liver): source for the R- vs S-isomer conversion point.
- Lowder J, Fallah S, Venditti C, Musa-Veloso K, Kotlov V. An open-label, acute clinical trial in adults to assess ketone levels, gastrointestinal tolerability, and sleepiness following consumption of (R)-1,3-butanediol. Front Physiol. 2023;14:1195702. PubMed ↗Open-label, uncontrolled, one-group acute study, n = 26; 3 × 11.5 g (R)-1,3-butanediol fasted; mean Cmax 2.10 ± 0.97 mM at 134 ± 57 min. Funded by the ingredient manufacturer; three authors were paid consultants to the funder; the funder was involved in study design and the decision to publish but not in data collection, analysis or writing. Kinetics and tolerability only.
- Falkenhain K, Daraei A, Little JP. The Effect of Novel Exogenous Ketone Supplements on Blood Beta-Hydroxybutyrate and Glucose. J Diet Suppl. 2024;21(1):38–52. PubMed ↗Matched 10 g crossover; rise-above-baseline figures on this page are calculations from the published values. The (R)-1,3-butanediol peak (1.2 ± 0.3 mM at ~40 min) is as reported by Lowder et al. 2023.
- Stubbs BJ, Cox PJ, Evans RD, et al. On the Metabolism of Exogenous Ketones in Humans. Front Physiol. 2017;8:848. PubMed ↗ · Study index
- Shaw DM, Merien F, Braakhuis A, Plews D, Laursen P, Dulson DK. The Effect of 1,3-Butanediol on Cycling Time-Trial Performance. Int J Sport Nutr Exerc Metab. 2019;29(5):466–473. PubMed ↗Racemic (R,S)-1,3-butanediol, 0.35 g/kg twice; cited on this page for reported tolerability only.
- Poffé C, Wyns F, Ramaekers M, Hespel P. Exogenous Ketosis Impairs 30-min Time-Trial Performance Independent of Bicarbonate Supplementation. Med Sci Sports Exerc. 2021;53(5):1068–1078. PubMed ↗ · Study index